首页 News 正文

On November 14th, AstraZeneca announced that Infineon&Co; Reg; (English trade name: IMFINZI®, common name: Duvalizumab) has officially obtained approval from the National Drug Administration on November 7th for the combination of gemcitabine and cisplatin for first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) in adult patients. This plan is the first approved immunotherapy plan for biliary tract cancer in China.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

因醉鞭名马幌 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    43